Prohost Biotechnology
   
   
Biotechnology Research and Investment
   
Home News and Comments Subscribe now!!! About us Login
     
Saturday May 17, 2008
Search
 
 
Prohost is ranked #1 from among 355 publications.
Some of our topics include:
Stem Cells
Genomics
Biotech industry news
Nanotechnology
FDA Approvals
Stock Performance
Breakthroughs in science.
M&As
Clinical trials - phase by phase.
...and much more

 
 
Welcome
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the headlines. However, selecting the biotechnology firms in which to invest requires not only an understanding of the company's finances, but also a knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
 
Biotech News and Comments
 
LPATH (LPTH): WHAT DID WE LEARN? 05/15/2008
What should we learn from a press release? Taking as an example the news announced by Lpath, we learned that the firm has the fundamentals indispensable for a development-stage biotechnology company. These fundamentals are usually overlooked by analysts, a leading cause for the undervaluation of many biotechnology firms.
 
BIOTECHNOLOGY EVOLUTION IS BREATHTA.... 05/14/2008
Biotechnology is, indeed, evolving with astonishing high speed towards unveiling the body’s biological molecules involved in providing health, or causing diseases. We have news here. (for subscribers only)
 
GRAFT VS. HOST DISEASE (GvHD) 05/08/2008
In the news, the FDA has given clearance for Osiris to initiate an expanded access treatment program for Prochymal. What is GVHD and how big is the story (For subscribers Only)
 
PROHOST E-LETTER #271 05/06/2008
For Subscribers Only. Please click on the link on the Home page below.
 
WHAT HAPPENNED ON MARCH 28 IN A CHI.... 05/02/2008
A child suffering from Acute Lymphoblastic Leukemia (ALL), a cancer of the bone marrow and blood has been treated by transplanting human placenta-derived stem cells (HPDSCs. Read about the firm and the hospitals behind the groundbreaking transplant
 
 
 
Latest News Posted to subscribers
 
PROHOST E-LETTER # 271
Hype and opportunities. Cancer vaccine firms. Biotechnology near-term outperforming firms.
PROHOST E-LETTER # 270
PROHOST N-LETTER ISSUE #124
The Game. The biotech sector . The bad patterns. The rule of thumb and the biotech disciplines that will supervene. (For subscribers only.)
PROHOST E-LETTER #269
Time for the media to be serious about biotechnology
PROHOST N/E LETTER
FEAR, UNCERTAINTY = OPPORTUNITY
 
 
 
 
 
 
 
Member Area
Username
password
Forgot password?
click here
Reports For Sale
 
 
 
 
 
 
 
 
Home | Blog | Stocks | News and Comments | Subscribe now | About Us | Login